• Markets
    • icon
  • Companies
BXN · ASX

Bioxyne Limited (ASX:BXN)

AU$0.005

 -0.001 (-16.667%)
ASX:Live
26/07/2024 12:18:34 PM
HALO Ords GROWTH AUS Big Candle All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

BXN Overview

BXN Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About BXN

Website

N/A

Telephone

61.2.9078.8180

Address

Suite 506, Level 5 50 Clarence Street Sydney, New South Wales (NSW) 2000

Description

Bioxyne Ltd. engages in the research, development, market and distribution of health products. It operates through the following segments: Wholesale, Plant Based, and Direct Sales. The Wholesale segment covers operation in United States of America (USA), and Asia. The Plant Based segment includes manufacturing, commercialization, and distribution of plant-based products. The Direct Sales segment focuses on Australia, and Asia operation. The company was founded in 1998 and is headquartered in Sydney, Australia.

BXN Price Chart

Key Stats

Market Cap

AU$10.23M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.0 - 0.02

Trade Value (12mth)

AU$1,509.00

1 week

20%

1 month

20%

YTD

-45.45%

1 year

-68.42%

All time high

8.93

Key Fundamentals

EPS 3 yr Growth

55.600%

EBITDA Margin

-37.60%

Operating Cashflow

-$1m

Free Cash Flow Return

-9.90%

ROIC

-22.80%

Interest Coverage

N/A

Quick Ratio

1.90

Other Data

Shares on Issue (Fully Dilluted)

1902m

HALO Sector

Industrials

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

BXN Announcements

Latest Announcements

Date Announcements

01 July 24

Addendum to Cy Biopharma Announcement 14.5.2024

×

Addendum to Cy Biopharma Announcement 14.5.2024

14 May 24

BXN Signs Collaboration Agreement with Cy Biopharma AG

×

BXN Signs Collaboration Agreement with Cy Biopharma AG

13 May 24

Shares Out of Escrow

×

Shares Out of Escrow

30 April 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

22 April 24

Application for quotation of securities - BXN

×

Application for quotation of securities - BXN

22 April 24

Cleansing Notice

×

Cleansing Notice

18 April 24

Bioxyne Receives Firm Commitments to Raise $1.45 Million

×

Bioxyne Receives Firm Commitments to Raise $1.45 Million

18 April 24

Proposed issue of securities - BXN

×

Proposed issue of securities - BXN

25 March 24

Investor Presentation

×

Investor Presentation

25 March 24

Bioxyne to Host Webinar on 28 March 2024

×

Bioxyne to Host Webinar on 28 March 2024

22 March 24

Notification of cessation of securities - BXN

×

Notification of cessation of securities - BXN

22 March 24

Notification regarding unquoted securities - BXN

×

Notification regarding unquoted securities - BXN

29 February 24

Half Yearly Report and Accounts

×

Half Yearly Report and Accounts

05 February 24

Quarterly Report Listing Rule 4.7C.3

×

Quarterly Report Listing Rule 4.7C.3

05 February 24

BXN Awarded GMP Manufacturing License for Medical Cannabis

×

BXN Awarded GMP Manufacturing License for Medical Cannabis

29 January 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

17 November 23

Annual General Meeting Presentation

×

Annual General Meeting Presentation

17 November 23

Results of Meeting

×

Results of Meeting

17 November 23

Retirement of Director

×

Retirement of Director

17 November 23

Final Director's Interest Notice

×

Final Director's Interest Notice

06 November 23

Change in substantial holding

×

Change in substantial holding

31 October 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

19 October 23

BLS Builds Medicinal Business In Australia

×

BLS Builds Medicinal Business In Australia

18 October 23

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

18 October 23

Letter to Shareholders re Annual General Meeting Notice

×

Letter to Shareholders re Annual General Meeting Notice

BXN Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 11.1 50.0 -250.0 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock 0.00 0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -64.8 84.2 -535.6 Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.3 5.6 -3.3 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.00 0.00 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -26.7 0.4 -35.3 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 640 640 1,344 Lock Lock Lock
Basic m Lock Lock Lock Lock 640 640 1,344 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 2 2 5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -6.6 14.5 113.6 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 1 1 2 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 1 1 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.1 46.4 -63.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock 30.3 38.8 6.6 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 70 61 93 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock 0 0 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -26.9 40.2 -569.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -23.0 -12.0 -37.6 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -1 0 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.6 40.6 -503.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -27.1 -14.1 -39.8 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -1 0 -2 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock 0 0 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock 16.4 52.3 -720.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -23.5 -9.8 -37.6 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock 0 0 -1 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 4 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock 0 0 -1 Lock Lock Lock
     Growth % Lock Lock Lock Lock 264.2 707.9 -309.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock 0.0 0.2 -0.2 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 2 2 4 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 3 3 18 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -2 -2 -4 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 1 3 Lock Lock Lock
Equity $m Lock Lock Lock Lock 2 2 15 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 2 2 15 Lock Lock Lock
     Growth % Lock Lock Lock Lock -26.4 0.4 701.5 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -18.5 -8.1 -11.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -26.4 -12.5 -12.8 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -24.9 -17.6 -24.2 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -22.3 -12.5 -22.8 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock 2.4 23.1 -9.9 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -288.1 N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 3.3 7.5 2.0 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -85.2 -114.8 -25.4 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 3.4 2.9 2.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 2.9 2.6 1.9 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 63.8 76.9 63.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock 7.1 44.3 -31.3 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 5.7 11.0 9.8 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 2.6 4.4 7.4 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 1.2 1.3 1.5 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 8.3 3.9 23.4 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.8 0.8 0.3 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.8 0.8 0.3 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -24.4 -10.0 -39.5 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -19.2 -8.2 -11.5 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -18.5 -8.1 -11.0 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.4 1.5 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -26.4 -12.5 -12.8 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -26.4 -12.5 -12.8 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 141.2 83.8 49.4 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 63.5 33.1 37.3 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 204.6 117.0 86.7 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 67.4 34.8 43.1 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 137.3 82.2 43.6 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

BXN Shortsell

Frequently Asked Questions

The current share price of Bioxyne Limited (BXN:ASX) is AU$0.005.
The 52-week high share price for Bioxyne Limited (BXN:ASX) is AU$0.02.
The 52-week low share price for Bioxyne Limited (BXN:ASX)? is AU$0.00.
Bioxyne Limited (BXN:ASX) does not pay a dividend.
Bioxyne Limited (BXN:ASX) does not pay a dividend.
Bioxyne Limited (BXN:ASX) has a franking level of 0.0%.
Bioxyne Limited (BXN:ASX) is classified in the Industrials.
The current P/E ratio for Bioxyne Limited (BXN:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.